Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
Authors
Keywords
Prostate-specific membrane antigen, Prostate cancer, <sup>177</sup>Lu, Response, Overall survival
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 44, Issue 9, Pages 1448-1454
Publisher
Springer Nature
Online
2017-05-09
DOI
10.1007/s00259-017-3716-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617
- (2016) Carl Diedrich Schlenkhoff et al. CLINICAL NUCLEAR MEDICINE
- Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617
- (2016) Xiao Wei et al. CLINICAL NUCLEAR MEDICINE
- Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer
- (2016) Carl Diedrich Schlenkhoff et al. CLINICAL NUCLEAR MEDICINE
- Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer
- (2016) Kambiz Rahbar et al. CLINICAL NUCLEAR MEDICINE
- Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis
- (2016) K. Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
- (2016) Kambiz Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- 68 Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223 Ra: Proof of Concept
- (2016) Hojjat Ahmadzadehfar et al. JOURNAL OF NUCLEAR MEDICINE
- Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177 Lu-PSMA-617
- (2016) Justin Ferdinandus et al. JOURNAL OF NUCLEAR MEDICINE
- 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
- (2016) R. P. Baum et al. JOURNAL OF NUCLEAR MEDICINE
- The Role of Positron Emission Tomography With 68Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy
- (2016) Bhavan Prasad Rai et al. UROLOGY
- Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
- (2016) Hojjat Ahmadzadehfar et al. Oncotarget
- The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions
- (2015) A. Afshar-Oromieh et al. JOURNAL OF NUCLEAR MEDICINE
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study
- (2015) Hojjat Ahmadzadehfar et al. EJNMMI Research
- Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
- (2014) Christian M. Zechmann et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
- (2012) A. Afshar-Oromieh et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Re: Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
- (2012) P. W. Kantoff et al. JNCI-Journal of the National Cancer Institute
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now